TB Research

Reviewer response for version 1

Andrew Nicolson

Abstract

In July 2023, the World Health Organization (WHO) began recommending targeted next-generation sequencing (tNGS), due to its ability to detect resistance to many drugs with a single test. In March 2023, South Africa further adopted the GeneXpert® XDR cartridge, which detects mutations associated with resistance to second-line injectable drugs. Here, we consider the feasibility for implementing tNGS in South Africa, what such a facility might look like and the specific context of this upper-middle-income country. Whilst the WHO now recommends tNGS for TB diagnostics and DST, there are many economic and infrastructural challenges opposing its deployment. In lieu of this, we instead recommend a stratified diagnostic pipeline that utilises South Africa's existing GeneXpert technologies, in an attempt to reduce the costs associated with implementation of tNGS.

MeSH terms

  • GeneXpert MTB/RIF
  • Context (archaeology)
  • Diagnostic test
  • Software deployment
  • Medicine
  • First line
  • Business
  • Operations management
  • Operations research
  • Medical emergency